Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CYRX 
Cryoport Inc (CYRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/10/2025: CYRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -14.35% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 304.20M USD | Price to earnings Ratio - | 1Y Target Price 10.69 |
Price to earnings Ratio - | 1Y Target Price 10.69 | ||
Volume (30-day avg) 362683 | Beta 1.67 | 52 Weeks Range 4.58 - 20.11 | Updated Date 03/31/2025 |
52 Weeks Range 4.58 - 20.11 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.48 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-10 | When Before Market | Estimate -0.3064 | Actual -0.4271 |
Profitability
Profit Margin -50.25% | Operating Margin (TTM) -27.44% |
Management Effectiveness
Return on Assets (TTM) -4.98% | Return on Equity (TTM) -25.76% |
Valuation
Trailing PE - | Forward PE 58.14 | Enterprise Value 327183281 | Price to Sales(TTM) 1.33 |
Enterprise Value 327183281 | Price to Sales(TTM) 1.33 | ||
Enterprise Value to Revenue 1.43 | Enterprise Value to EBITDA -13 | Shares Outstanding 49910400 | Shares Floating 39615375 |
Shares Outstanding 49910400 | Shares Floating 39615375 | ||
Percent Insiders 2.67 | Percent Institutions 101.07 |
Analyst Ratings
Rating 3.73 | Target Price 11.3 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cryoport Inc
Company Overview
History and Background
Cryoport, Inc. was founded in 1999. It began focusing on temperature-controlled logistics solutions for the life sciences industry, specializing in the cryopreservation and transport of biological materials. Over time, Cryoport expanded its service offerings and geographical reach through strategic acquisitions and organic growth.
Core Business Areas
- Cryoport Systems: Provides temperature-controlled logistics solutions, including specialized packaging, information management, and transportation services, for the life sciences industry. This encompasses the transport of cell and gene therapies, reproductive medicine materials, and animal health products.
- Cryoport Solutions: Offers biostorage and cryopreservation services. These services complement the transport activities to offer end-to-end solution for clients.
- MVE Biological Solutions: Manufactures cryogenic freezers and related equipment used for the storage of biological materials.
Leadership and Structure
Jerrell Shelton is the current CEO. The company has a board of directors and a structured leadership team overseeing various departments such as operations, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Cryoport Express Shippers: Specialized cryogenic shipping containers used for transporting biological materials at ultra-low temperatures. Market share is estimated to be around 60-70% in cell and gene therapy logistics. Competitors include World Courier, Marken (UPS company), and FedEx Custom Critical.
- Cryoportal Information Management System: A cloud-based platform for managing the logistics and tracking of biological materials. It provides real-time visibility and chain-of-custody documentation. No specific market share available; adoption is driven by integration with Cryoport's logistics services. Competitors include custom-built systems by large pharma companies and smaller logistics tracking platforms.
- MVE Freezers: MVE Biological Solutions' line of cryogenic freezers used for long-term storage of biological samples. Competitors include Thermo Fisher Scientific and Chart Industries.
Market Dynamics
Industry Overview
The life sciences logistics industry is experiencing rapid growth, driven by the increasing demand for cell and gene therapies, personalized medicine, and biopharmaceutical products. The industry is characterized by stringent regulatory requirements, complex supply chains, and the need for precise temperature control.
Positioning
Cryoport Inc. is a leading provider of temperature-controlled logistics solutions for the life sciences industry, particularly in the rapidly growing cell and gene therapy market. Its competitive advantages include its specialized expertise, proprietary technology, and global network.
Total Addressable Market (TAM)
The global market for cell and gene therapy logistics is estimated to be several billion dollars and growing rapidly. Cryoport is well-positioned to capture a significant share of this TAM given its dominant position in CGT logistics.
Upturn SWOT Analysis
Strengths
- Specialized expertise in cryogenic logistics
- Proprietary technology and infrastructure
- Strong relationships with leading biopharmaceutical companies
- Global network and reach
- Dominant position in cell and gene therapy logistics
Weaknesses
- High reliance on the biopharmaceutical industry
- Exposure to regulatory changes
- Potential for disruptions in the supply chain
- Can be considered expensive compared to alternate solutions
Opportunities
- Expansion into new therapeutic areas
- Geographic expansion into emerging markets
- Strategic acquisitions and partnerships
- Development of new technologies and services
Threats
- Increased competition from other logistics providers
- Economic downturns affecting the biopharmaceutical industry
- Cybersecurity threats
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- UPS (UPS)
- F DX (FDX)
- Thermo Fisher Scientific (TMO)
Competitive Landscape
Cryoport Inc. is a leader in CGT logistics, with a focus on quality and specialization. Competitors like UPS and FedEx have broad logistics capabilities but less specialization in cryogenic and temperature-controlled environments.
Major Acquisitions
MVE Biological Solutions
- Year: 2020
- Acquisition Price (USD millions): 320
- Strategic Rationale: Expanded Cryoport's product offerings to include cryogenic freezers and related equipment, strengthening its end-to-end solution.
CryoPDP
- Year: 2020
- Acquisition Price (USD millions): 27
- Strategic Rationale: Added specialized temperature-controlled logistics capabilities in the EMEA region.
Growth Trajectory and Initiatives
Historical Growth: Cryoport has experienced significant growth in recent years, driven by the increasing demand for its logistics solutions in the cell and gene therapy market.
Future Projections: Analyst estimates suggest continued growth for Cryoport, driven by the expanding cell and gene therapy market.
Recent Initiatives: Recent initiatives include strategic acquisitions, partnerships, and the development of new technologies and services to enhance its logistics capabilities.
Summary
Cryoport is a strong player in temperature-controlled logistics, particularly in the burgeoning cell and gene therapy space. Their specialized expertise and strategic acquisitions have solidified their position. Potential weaknesses include reliance on the biopharma industry and intense competition from larger logistics firms. The company should capitalize on expansion opportunities and maintain a focus on quality to maintain its leadership.
Similar Companies
- UPS
- FDX
- TMO
- LH
- IQV
Sources and Disclaimers
Data Sources:
- Cryoport Inc. investor relations website
- SEC filings
- Market research reports
- Industry news articles
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may vary. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cryoport Inc
Exchange NASDAQ | Headquaters Brentwood, TN, United States | ||
IPO Launch date 2005-03-15 | Chairman, President & CEO Mr. Jerrell W. Shelton | ||
Sector Industrials | Industry Integrated Freight & Logistics | Full time employees 1090 | Website https://www.cryoportinc.com |
Full time employees 1090 | Website https://www.cryoportinc.com | ||
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport Express Cryogenic HV3 Shipping System (HV3); Smartpak II Condition Monitoring System and Tec4Med; Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport System Bioservices, such as controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release services. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPD, a temperature-controlled logistics solution; MVE Biological Solutions Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is based in Brentwood, Tennessee.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.